Latest news

KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Monoclonal Antibody Candidate

KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology

Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Phar...

Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization challenges.

KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality...